Trial Title:
Testing Immunotherapy (Atezolizumab) With or Without Chemotherapy in Locoregional MSI-H/dMMR Gastric and Gastroesophageal Junction (GEJ) Cancer
NCT ID:
NCT05836584
Condition:
Clinical Stage I Gastric Cancer AJCC v8
Clinical Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8
Clinical Stage II Gastric Cancer AJCC v8
Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8
Clinical Stage III Gastric Cancer AJCC v8
Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8
Clinical Stage IVA Gastric Cancer AJCC v8
Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8
Gastric Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
Conditions: Official terms:
Adenocarcinoma
Stomach Neoplasms
Esophageal Neoplasms
Calcium, Dietary
Leucovorin
Folic Acid
Docetaxel
Capecitabine
Oxaliplatin
Fluorouracil
Atezolizumab
Calcium
Antibodies, Monoclonal
Levoleucovorin
Study type:
Interventional
Study phase:
Phase 2
Overall status:
Recruiting
Study design:
Allocation:
Randomized
Intervention model:
Parallel Assignment
Primary purpose:
Treatment
Masking:
None (Open Label)
Intervention:
Intervention type:
Biological
Intervention name:
Atezolizumab
Description:
Given IV
Arm group label:
Arm A (chemotherapy, atezolizumab)
Arm group label:
Arm B (atezolizumab)
Other name:
MPDL 3280A
Other name:
MPDL 328OA
Other name:
MPDL-3280A
Other name:
MPDL3280A
Other name:
MPDL328OA
Other name:
RG 7446
Other name:
RG-7446
Other name:
RG7446
Other name:
RO 5541267
Other name:
RO-5541267
Other name:
RO5541267
Other name:
Tecentriq
Intervention type:
Procedure
Intervention name:
Biospecimen Collection
Description:
Undergo collection of blood samples
Arm group label:
Arm A (chemotherapy, atezolizumab)
Arm group label:
Arm B (atezolizumab)
Other name:
Biological Sample Collection
Other name:
Biospecimen Collected
Other name:
Specimen Collection
Intervention type:
Drug
Intervention name:
Capecitabine
Description:
Given PO
Arm group label:
Arm A (chemotherapy, atezolizumab)
Other name:
Ro 09-1978/000
Other name:
Xeloda
Intervention type:
Procedure
Intervention name:
Computed Tomography
Description:
Undergo CT or PET/CT
Arm group label:
Arm A (chemotherapy, atezolizumab)
Arm group label:
Arm B (atezolizumab)
Other name:
CAT
Other name:
CAT Scan
Other name:
Computed Axial Tomography
Other name:
Computerized Axial Tomography
Other name:
Computerized axial tomography (procedure)
Other name:
Computerized Tomography
Other name:
Computerized Tomography (CT) scan
Other name:
CT
Other name:
CT Scan
Other name:
tomography
Intervention type:
Drug
Intervention name:
Docetaxel
Description:
Given IV
Arm group label:
Arm A (chemotherapy, atezolizumab)
Other name:
Docecad
Other name:
RP 56976
Other name:
RP-56976
Other name:
RP56976
Other name:
Taxotere
Other name:
Taxotere Injection Concentrate
Intervention type:
Procedure
Intervention name:
Echocardiography
Description:
Undergo ECHO
Arm group label:
Arm A (chemotherapy, atezolizumab)
Arm group label:
Arm B (atezolizumab)
Other name:
EC
Intervention type:
Drug
Intervention name:
Fluorouracil
Description:
Given IV
Arm group label:
Arm A (chemotherapy, atezolizumab)
Other name:
5 Fluorouracil
Other name:
5 Fluorouracilum
Other name:
5 FU
Other name:
5-Fluoro-2,4(1H, 3H)-pyrimidinedione
Other name:
5-Fluorouracil
Other name:
5-Fluracil
Other name:
5-Fu
Other name:
5FU
Other name:
AccuSite
Other name:
Carac
Other name:
Fluoro Uracil
Other name:
Fluouracil
Other name:
Flurablastin
Other name:
Fluracedyl
Other name:
Fluracil
Other name:
Fluril
Other name:
Fluroblastin
Other name:
Ribofluor
Other name:
Ro 2-9757
Other name:
Ro-2-9757
Intervention type:
Drug
Intervention name:
Leucovorin Calcium
Description:
Given IV
Arm group label:
Arm A (chemotherapy, atezolizumab)
Other name:
Adinepar
Other name:
Calcifolin
Other name:
Calcium (6S)-Folinate
Other name:
Calcium Folinate
Other name:
Calcium Leucovorin
Other name:
Calfolex
Other name:
Calinat
Other name:
Cehafolin
Other name:
Citofolin
Other name:
Citrec
Other name:
Citrovorum Factor
Other name:
Cromatonbic Folinico
Other name:
Dalisol
Other name:
Disintox
Other name:
Divical
Other name:
Ecofol
Other name:
Emovis
Other name:
Factor, Citrovorum
Other name:
Flynoken A
Other name:
Folaren
Other name:
Folaxin
Other name:
FOLI-cell
Other name:
Foliben
Other name:
Folidan
Other name:
Folidar
Other name:
Folinac
Other name:
Folinate Calcium
Other name:
folinic acid
Other name:
Folinic Acid Calcium Salt Pentahydrate
Other name:
Folinoral
Other name:
Folinvit
Other name:
Foliplus
Other name:
Folix
Other name:
Imo
Other name:
Lederfolat
Other name:
Lederfolin
Other name:
Leucosar
Other name:
leucovorin
Other name:
Rescufolin
Other name:
Rescuvolin
Other name:
Tonofolin
Other name:
Wellcovorin
Intervention type:
Procedure
Intervention name:
Lymphadenectomy
Description:
Undergo lymphadenectomy
Arm group label:
Arm A (chemotherapy, atezolizumab)
Arm group label:
Arm B (atezolizumab)
Other name:
excision of the lymph node
Other name:
Lymph Node Dissection
Other name:
Lymph Node Excision
Intervention type:
Procedure
Intervention name:
Magnetic Resonance Imaging
Description:
Undergo MRI
Arm group label:
Arm A (chemotherapy, atezolizumab)
Arm group label:
Arm B (atezolizumab)
Other name:
Magnetic Resonance
Other name:
Magnetic Resonance Imaging (MRI)
Other name:
Magnetic resonance imaging (procedure)
Other name:
Magnetic Resonance Imaging Scan
Other name:
Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance
Other name:
MR
Other name:
MR Imaging
Other name:
MRI
Other name:
MRI Scan
Other name:
MRIs
Other name:
NMR Imaging
Other name:
NMRI
Other name:
Nuclear Magnetic Resonance Imaging
Other name:
sMRI
Other name:
Structural MRI
Intervention type:
Drug
Intervention name:
Oxaliplatin
Description:
Given IV
Arm group label:
Arm A (chemotherapy, atezolizumab)
Other name:
1-OHP
Other name:
Ai Heng
Other name:
Aiheng
Other name:
Dacotin
Other name:
Dacplat
Other name:
Diaminocyclohexane Oxalatoplatinum
Other name:
Eloxatin
Other name:
Eloxatine
Other name:
Elplat
Other name:
JM 83
Other name:
JM-83
Other name:
JM83
Other name:
Oxalatoplatin
Other name:
Oxalatoplatinum
Other name:
RP 54780
Other name:
RP-54780
Other name:
RP54780
Other name:
SR 96669
Other name:
SR-96669
Other name:
SR96669
Intervention type:
Procedure
Intervention name:
Positron Emission Tomography
Description:
Undergo PET/CT
Arm group label:
Arm A (chemotherapy, atezolizumab)
Arm group label:
Arm B (atezolizumab)
Other name:
Medical Imaging, Positron Emission Tomography
Other name:
PET
Other name:
PET Scan
Other name:
Positron emission tomography (procedure)
Other name:
Positron Emission Tomography Scan
Other name:
Positron-Emission Tomography
Other name:
proton magnetic resonance spectroscopic imaging
Other name:
PT
Intervention type:
Procedure
Intervention name:
Surgical Procedure
Description:
Undergo surgery
Arm group label:
Arm A (chemotherapy, atezolizumab)
Arm group label:
Arm B (atezolizumab)
Other name:
Operation
Other name:
Surgery
Other name:
Surgery Type
Other name:
Surgery, NOS
Other name:
Surgical
Other name:
Surgical Intervention
Other name:
Surgical Interventions
Other name:
Surgical Procedures
Other name:
Type of Surgery
Summary:
This phase II trial compares atezolizumab in combination with chemotherapy (docetaxel,
oxaliplatin, leucovorin calcium, fluorouracil, capecitabine) to atezolizumab alone for
controlling the growth and/or spreading of the disease in patients with gastric or
gastroesophageal junction (JEG) cancer that has not spread from where it first started
(local) or only has spread to nearby lymph nodes or tissue (locoregional) and has high
microsatellite instability (MSI-H) and mismatch repair deficiency (dMMR). The mismatch
repair (MMR) system in the body corrects errors made during the copying of DNA and serves
as a proofreading function. If this system isn't working correctly, mutations (changes)
in DNA occur which can allow the cancer to grow or spread. This is called dMMR (deficient
mismatch repair) . MSI-H describes cancer cells that have a high number of mutations
within microsatellites. For example, microsatellite testing that shows mutations in 30%
or more microsatellites is called microsatellite instability-high (MSI-H).
Microsatellites are short, repeated sequences of DNA. There is evidence that MSI-H/ dMMR
gastric or GEJ tumors respond well to immunotherapy. Immunotherapy with monoclonal
antibodies, such as atezolizumab, may help the body's immune system attack the cancer,
and may interfere with the ability of tumor cells to grow and spread. Docetaxel is in a
class of medications called taxanes. It stops tumor cells from growing and dividing and
may kill them. Oxaliplatin is in a class of medications called platinum-containing
antineoplastic agents. It damages the cell's DNA and may kill tumor cells. Capecitabine
is in a class of medications called antimetabolites. It is taken up by tumor cells and
breaks down into fluorouracil, a substance that kills tumor cells. Chemotherapy drugs
such as leucovorin calcium and fluorouracil work in different ways to stop the growth of
tumor cells, either by killing the cells, by stopping them from dividing, or by stopping
them from spreading. Using atezolizumab as immunotherapy with and following chemotherapy
versus atezolizumab alone prior to and after surgery may shrink or stabilize the tumor in
patients with MSI-H/dMMR localized gastric or GEJ cancer and may increase the length of
time after treatment that cancer does not come back or get worse.
Detailed description:
PRIMARY OBJECTIVE:
I. To compare three-year event-free survival (EFS) following the administration of
perioperative atezolizumab and chemotherapy versus atezolizumab alone in patients with
resectable microsatellite instability-high (MSI-H)/mismatch repair deficiency (dMMR)
gastric and gastroesophageal junction (GEJ) cancer.
SECONDARY OBJECTIVES:
I. To assess tumor regression grade (TRG) rates following the administration of
perioperative atezolizumab and chemotherapy versus atezolizumab in patients with
resectable MSI-H/dMMR gastric and gastroesophageal junction (GEJ) cancer.
II. To assess overall survival (OS) following the administration of perioperative
atezolizumab and chemotherapy versus atezolizumab in patients with resectable MSI-H/dMMR
gastric and gastroesophageal junction (GEJ) cancer.
III. To assess the toxicity associated with the administration of perioperative
atezolizumab and chemotherapy versus atezolizumab in patients with resectable MSI-H/dMMR
gastric and gastroesophageal junction (GEJ) cancer.
IV. To correlate circulating tumor-derived deoxyribonucleic acid (ctDNA) clearance
(defined as > 50% reduction or a reduction to undetectable levels) with TRG, EFS and OS.
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM A:
NEOADJUVANT THERAPY: Patients receive physician's choice of chemotherapy regimen
consisting of 4 cycles of docetaxel intravenously (IV), oxaliplatin IV, leucovorin
calcium IV, and fluorouracil IV (FLOT) or 4 cycles of oxaliplatin IV, leucovorin calcium
IV, and fluorouracil IV (mFOLFOX) or 3 cycles of oxaliplatin IV and capecitabine orally
(PO) (CAPOX) in addition to atezolizumab IV on study.
SURGERY: Patients undergo surgery with lymphadenectomy on study.
ADJUVANT THERAPY: Patients receive FLOT, mFOLFOX, or CAPOX and atezolizumab IV as in
Neoadjuvant Therapy and then receive atezolizumab IV alone.
ARM B:
NEOADJUVANT THERAPY: Patients receive 3 cycles of atezolizumab IV on study.
SURGERY: Patients undergo surgery with lymphadenectomy on study.
ADJUVANT THERAPY: Patients receive 9 cycles of atezolizumab IV on study.
All patients also undergo computed tomography (CT) or magnetic resonance imaging (MRI)
throughout the trial. Patients may optionally undergo positron emission tomography
(PET)/CT and/or collection of blood samples throughout the trial. Patients may also
undergo echocardiography (ECHO) throughout the trial as clinically indicated.
Patients are followed up for 10 years from the date of randomization.
Criteria for eligibility:
Criteria:
Inclusion Criteria:
- Patient must be >= 18 years of age
- Patient must have histologically or cytologically confirmed diagnosis of gastric or
gastroesophageal junction adenocarcinoma that is MSI-H/dMMR (microsatellite
instability-high/mismatch repair deficient) as determined by one of three methods:
- Deficient deoxyribonucleic acid (DNA) mismatch repair protein (MMR) expression
status: MMR status must be assessed by immunohistochemistry (IHC) for MMR
protein expression (MLH1, MSH2, MSH6, PMS2) where loss of one or more proteins
indicates dMMR. dMMR may be determined either locally or by site-selected
reference lab by Clinical Laboratory Improvement Act (CLIA)-certified assay
- NOTE: Loss of MLH1 and PMS2 commonly occur together
- Polymerase chain reaction (PCR) determined microsatellite instability
- MSI-H tumor status determined by next-generation sequencing
- Patient must have previously untreated localized gastric, or Siewert type II or III
GEJ (gastroesophageal junction) adenocarcinoma. Tumors must be staged as T2 or
greater primary lesion or be any T stage with the presence of positive locoregional
lymph nodes- N+ (clinical nodes) without evidence of metastatic disease
- Siewert type II tumors: tumors located between 1 cm proximal and 2 cm distal to
the GEJ
- Siewert type III tumors: tumors located between 2 and 5 cm distal to GEJ
- Patient must be amenable to surgical resection with therapeutic intent
- Patient must have an Eastern Cooperative Oncology Group (ECOG) performance status
0-2
- Absolute neutrophil count (ANC) >= 1,500/mcL (obtained =< 14 days prior to
randomization)
- Platelets >= 100,000/mcL (obtained =< 14 days prior to randomization)
- Hemoglobin >= 9 g/dL (obtained =< 14 days prior to randomization)
- Total bilirubin =< 1.5 x institutional upper limit of normal (ULN) OR direct
bilirubin =< ULN (for patients with total bilirubin > 1.5 x ULN) (obtained =< 14
days prior to randomization)
- Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase
[SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase
[SGPT]): x =< 3 institutional ULN (obtained =< 14 days prior to randomization)
- Creatinine =< 1.5 x institutional ULN OR glomerular filtration rate (GFR) > 50
mL/min/1.73m^2 (obtained =< 14 days prior to randomization)
- Albumin >= 2.5 g/dL (obtained =< 14 days prior to randomization)
- International normalized ratio (INR) OR prothrombin time (PT) =< 1.5 x ULN (unless
patient is receiving anticoagulant therapy as long as PT or partial thromboplastin
time [PTT] is within therapeutic range of intended use of anticoagulants) (obtained
=< 14 days prior to randomization)
- Activated partial thromboplastin time (aPTT) =< 1.5 x ULN (unless patient is
receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of
intended use of anticoagulants) (obtained =< 14 days prior to randomization)
- Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral
therapy with undetectable viral load within 6 months are eligible for this trial
- Patient must have no contraindications to receive one of the chemotherapy regimens:
FLOT or mFOLFOX / CAPOX
- Patient must not have had prior potentially curative surgery for carcinoma of the
stomach/GEJ
- Patient must not receive any other standard anti-cancer therapy or experimental
agent concurrently with the study drugs
- Patient must have recovered from clinically significant adverse events of their most
recent therapy/intervention prior to randomization
- Patients with known history or current symptoms of cardiac disease, or history of
treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac
function using the New York Heart Association Functional Classification. To be
eligible for this trial, patients should be class 2B or better
- Patients with a prior or concurrent malignancy whose natural history or treatment
does not have the potential to interfere with the safety or efficacy assessment of
the investigational regimen are eligible for this trial
- Patient must have chest/abdomen/pelvis CT completed within 4 weeks prior to
randomization
- Patient may not have received prior treatment with an immune checkpoint inhibitor
(anti-PD-1, anti-PDL-1, anti-PDL-2, anti-CTLA4 monoclonal antibody)
- Patient must not have received any live vaccines within 30 days prior to
randomization and while participating in the study. Live vaccines include, but are
not limited to, the following: measles, mumps, rubella, chicken pox, yellow fever,
rabies, Bacillus Calmette-Guerin (BCG), and typhoid (oral) vaccine. Patients are
permitted to receive inactivated vaccines and any non-live vaccines including those
for the seasonal influenza and coronavirus disease 2019 (COVID-19) (Note: intranasal
influenza vaccines, such as Flu-Mist [registered trademark] are live attenuated
vaccines and are not allowed). If possible, it is recommended to separate study drug
administration from vaccine administration by about a week (primarily, in order to
minimize an overlap of adverse events)
- Patient must not have active autoimmune disease or history of autoimmune disease
that might recur, which may affect vital organ function or require immune
suppressive treatment including systemic corticosteroids. These include but are not
limited to patients with a history of immune related neurologic disease, multiple
sclerosis, autoimmune (demyelinating) neuropathy, Guillain- Barre syndrome,
myasthenia gravis; systemic autoimmune disease such as systemic lupus erythematosus
(SLE), connective tissue disease, scleroderma, inflammatory bowel disease (IBD),
Crohn's, ulcerative colitis and hepatitis. Patients with a history of toxic
epidermal necrolysis (TEN), Stevens-Johnson syndrome, or phospholipid syndrome are
ineligible because of the risk of recurrence or exacerbation of disease. Patients
with vitiligo, endocrine deficiencies including thyroiditis managed with replacement
hormones including physiologic corticosteroids are eligible. Patients with
rheumatoid arthritis and other arthropathies, Sjogren's syndrome and psoriasis
controlled with topical medication and patients with positive serology, such as
antinuclear antibodies (ANA), anti-thyroid antibodies should be evaluated for the
presence of target organ involvement and potential need for systemic treatment but
otherwise are eligible.
- Patients are permitted to enroll if they have vitiligo, type I diabetes
mellitus, residual hypothyroidism due to autoimmune condition only requiring
hormone replacement, psoriasis not requiring systemic treatment, or conditions
not expected to recur in the absence of an external trigger (precipitating
event)
- Patients must not be receiving systemic steroid therapy equivalent to > 10 mg
prednisone per day or any other form of immunosuppressive therapy within 7 days
prior to randomization. Topical corticosteroid or occasional inhaled corticosteroids
are allowed
- Patient must not have known interstitial lung disease that is symptomatic or may
interfere with the detection or management of suspected drug-related pulmonary
toxicity, and must not have a known history of prior pneumonitis requiring treatment
with steroids, or any evidence of active, non-infectious pneumonitis
- Patient must not have a known history of active TB (Bacillus Tuberculosis)
- Patient must not have any hypersensitivity to atezolizumab or any of its excipients
- Patient must not have received any prior chemotherapy, targeted small molecule
therapy, or radiation therapy for their MSI-H/dMMR gastric and GEJ cancer
- Patient must not have had an allogeneic bone marrow/stem, cell or solid organ
transplant
- Patient must not have a history or current evidence of any condition (e.g., known
deficiency of the enzyme dihydropyrimidine dehydrogenase [DPD]), therapy, or
laboratory abnormality that might confound the results of the trial, interfere with
the patient's participation for the full duration of the trial, or is not in the
best interest of the patient to participate, in the opinion of the treating
investigator
- Patient must not have any condition that would interfere with the cooperation with
the requirements of this trial
- Patient must not be pregnant or breast-feeding due to the potential harm to an
unborn fetus and possible risk for adverse events in nursing infants with the
treatment regimens being used
- All patients of childbearing potential must have a blood test or urine study
within 14 days prior to randomization to rule out pregnancy
- A patient of childbearing potential is defined as anyone, regardless of sexual
orientation or whether they have undergone tubal ligation, who meets the
following criteria: 1) has achieved menarche at some point, 2) has not
undergone a hysterectomy or bilateral oophorectomy; or 3) has not been
naturally postmenopausal (amenorrhea following cancer therapy does not rule out
childbearing potential) for at least 24 consecutive months (i.e., has had
menses at any time in the preceding 24 consecutive months)
- Patient must not expect to conceive or father children by using accepted and
effective method(s) of contraception or by abstaining from sexual intercourse while
on protocol treatment. Patients of childbearing potential must continue
contraception measures for 5 months after the last dose of atezolizumab and for 9
months after the last dose of chemotherapy. Male patients with partners of
childbearing potential must continue contraception measures for 6 months after the
last dose of chemotherapy. Patients of childbearing potential must also not
breastfeed while on treatment and for 5 months after the last dose of atezolizumab
and for 3 months after the last dose of chemotherapy
- Patient must have the ability to understand and the willingness to sign a written
informed consent document. Patients with impaired decision-making capacity (IDMC)
who have a legally authorized representative (LAR) or caregiver and/or family member
available will also be considered eligible
- For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV
viral load must be undetectable on suppressive therapy, if indicated
- Patients with a history of hepatitis C virus (HCV) infection must have been treated
and cured. For patients with HCV infection who are currently on treatment, they are
eligible if they have an undetectable HCV viral load
- The investigator must declare the chemotherapy regimen their patient will receive
(FLOT or mFOLFOX / CAPOX) prior to randomization
Gender:
All
Minimum age:
18 Years
Maximum age:
N/A
Healthy volunteers:
No
Locations:
Facility:
Name:
Kaiser Permanente Dublin
Address:
City:
Dublin
Zip:
94568
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
877-642-4691
Investigator:
Last name:
Tilak K. Sundaresan
Email:
Principal Investigator
Facility:
Name:
Kaiser Permanente-Fremont
Address:
City:
Fremont
Zip:
94538
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
877-642-4691
Email:
Kpoct@kp.org
Investigator:
Last name:
Tilak K. Sundaresan
Email:
Principal Investigator
Facility:
Name:
Kaiser Permanente-Fresno
Address:
City:
Fresno
Zip:
93720
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
877-642-4691
Email:
Kpoct@kp.org
Investigator:
Last name:
Tilak K. Sundaresan
Email:
Principal Investigator
Facility:
Name:
Kaiser Permanente-Modesto
Address:
City:
Modesto
Zip:
95356
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
877-642-4691
Email:
Kpoct@kp.org
Investigator:
Last name:
Tilak K. Sundaresan
Email:
Principal Investigator
Facility:
Name:
Kaiser Permanente-Oakland
Address:
City:
Oakland
Zip:
94611
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
877-642-4691
Email:
Kpoct@kp.org
Investigator:
Last name:
Tilak K. Sundaresan
Email:
Principal Investigator
Facility:
Name:
Kaiser Permanente-Roseville
Address:
City:
Roseville
Zip:
95661
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
877-642-4691
Email:
Kpoct@kp.org
Investigator:
Last name:
Tilak K. Sundaresan
Email:
Principal Investigator
Facility:
Name:
Kaiser Permanente Downtown Commons
Address:
City:
Sacramento
Zip:
95814
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
877-642-4691
Email:
kpoct@kp.org
Investigator:
Last name:
Tilak K. Sundaresan
Email:
Principal Investigator
Facility:
Name:
Kaiser Permanente-South Sacramento
Address:
City:
Sacramento
Zip:
95823
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
877-642-4691
Email:
Kpoct@kp.org
Investigator:
Last name:
Tilak K. Sundaresan
Email:
Principal Investigator
Facility:
Name:
Kaiser Permanente-San Francisco
Address:
City:
San Francisco
Zip:
94115
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
877-642-4691
Email:
Kpoct@kp.org
Investigator:
Last name:
Tilak K. Sundaresan
Email:
Principal Investigator
Facility:
Name:
Kaiser Permanente-Santa Teresa-San Jose
Address:
City:
San Jose
Zip:
95119
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
877-642-4691
Email:
Kpoct@kp.org
Investigator:
Last name:
Tilak K. Sundaresan
Email:
Principal Investigator
Facility:
Name:
Kaiser Permanente San Leandro
Address:
City:
San Leandro
Zip:
94577
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
877-642-4691
Email:
Kpoct@kp.org
Investigator:
Last name:
Tilak K. Sundaresan
Email:
Principal Investigator
Facility:
Name:
Kaiser San Rafael-Gallinas
Address:
City:
San Rafael
Zip:
94903
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
877-642-4691
Email:
Kpoct@kp.org
Investigator:
Last name:
Tilak K. Sundaresan
Email:
Principal Investigator
Facility:
Name:
Kaiser Permanente Medical Center - Santa Clara
Address:
City:
Santa Clara
Zip:
95051
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
877-642-4691
Email:
Kpoct@kp.org
Investigator:
Last name:
Tilak K. Sundaresan
Email:
Principal Investigator
Facility:
Name:
Kaiser Permanente-Santa Rosa
Address:
City:
Santa Rosa
Zip:
95403
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
877-642-4691
Email:
Kpoct@kp.org
Investigator:
Last name:
Tilak K. Sundaresan
Email:
Principal Investigator
Facility:
Name:
Kaiser Permanente-South San Francisco
Address:
City:
South San Francisco
Zip:
94080
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
877-642-4691
Email:
Kpoct@kp.org
Investigator:
Last name:
Tilak K. Sundaresan
Email:
Principal Investigator
Facility:
Name:
Kaiser Permanente-Vallejo
Address:
City:
Vallejo
Zip:
94589
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
877-642-4691
Email:
Kpoct@kp.org
Investigator:
Last name:
Tilak K. Sundaresan
Email:
Principal Investigator
Facility:
Name:
Kaiser Permanente-Walnut Creek
Address:
City:
Walnut Creek
Zip:
94596
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
877-642-4691
Email:
Kpoct@kp.org
Investigator:
Last name:
Tilak K. Sundaresan
Email:
Principal Investigator
Facility:
Name:
Beebe South Coastal Health Campus
Address:
City:
Millville
Zip:
19967
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
302-291-6730
Email:
research@beebehealthcare.org
Investigator:
Last name:
Gregory A. Masters
Email:
Principal Investigator
Facility:
Name:
Helen F Graham Cancer Center
Address:
City:
Newark
Zip:
19713
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
302-623-4450
Email:
lbarone@christianacare.org
Investigator:
Last name:
Gregory A. Masters
Email:
Principal Investigator
Facility:
Name:
Medical Oncology Hematology Consultants PA
Address:
City:
Newark
Zip:
19713
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
302-623-4450
Email:
lbarone@christianacare.org
Investigator:
Last name:
Gregory A. Masters
Email:
Principal Investigator
Facility:
Name:
Beebe Health Campus
Address:
City:
Rehoboth Beach
Zip:
19971
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
302-291-6730
Email:
research@beebehealthcare.org
Investigator:
Last name:
Gregory A. Masters
Email:
Principal Investigator
Facility:
Name:
Kaiser Permanente Moanalua Medical Center
Address:
City:
Honolulu
Zip:
96819
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
808-432-5195
Email:
shelley.a.clark@kp.org
Investigator:
Last name:
Tilak K. Sundaresan
Email:
Principal Investigator
Facility:
Name:
Illinois CancerCare-Bloomington
Address:
City:
Bloomington
Zip:
61704
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
309-243-3605
Email:
andersonj@illinoiscancercare.com
Investigator:
Last name:
Bryan A. Faller
Email:
Principal Investigator
Facility:
Name:
Illinois CancerCare-Canton
Address:
City:
Canton
Zip:
61520
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
309-243-3605
Email:
andersonj@illinoiscancercare.com
Investigator:
Last name:
Bryan A. Faller
Email:
Principal Investigator
Facility:
Name:
Illinois CancerCare-Carthage
Address:
City:
Carthage
Zip:
62321
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
309-243-3605
Email:
andersonj@illinoiscancercare.com
Investigator:
Last name:
Bryan A. Faller
Email:
Principal Investigator
Facility:
Name:
Carle at The Riverfront
Address:
City:
Danville
Zip:
61832
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
800-446-5532
Email:
Research@Carle.com
Investigator:
Last name:
Suparna Mantha
Email:
Principal Investigator
Facility:
Name:
Cancer Care Specialists of Illinois - Decatur
Address:
City:
Decatur
Zip:
62526
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
217-876-4762
Email:
morganthaler.jodi@mhsil.com
Investigator:
Last name:
Bryan A. Faller
Email:
Principal Investigator
Facility:
Name:
Illinois CancerCare-Dixon
Address:
City:
Dixon
Zip:
61021
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
815-285-7800
Investigator:
Last name:
Bryan A. Faller
Email:
Principal Investigator
Facility:
Name:
Carle Physician Group-Effingham
Address:
City:
Effingham
Zip:
62401
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
800-446-5532
Email:
Research@carle.com
Investigator:
Last name:
Suparna Mantha
Email:
Principal Investigator
Facility:
Name:
Crossroads Cancer Center
Address:
City:
Effingham
Zip:
62401
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
217-876-4762
Email:
morganthaler.jodi@mhsil.com
Investigator:
Last name:
Bryan A. Faller
Email:
Principal Investigator
Facility:
Name:
Illinois CancerCare-Eureka
Address:
City:
Eureka
Zip:
61530
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
309-243-3605
Email:
andersonj@illinoiscancercare.com
Investigator:
Last name:
Bryan A. Faller
Email:
Principal Investigator
Facility:
Name:
Illinois CancerCare-Galesburg
Address:
City:
Galesburg
Zip:
61401
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
309-243-3605
Email:
andersonj@illinoiscancercare.com
Investigator:
Last name:
Bryan A. Faller
Email:
Principal Investigator
Facility:
Name:
Illinois CancerCare-Kewanee Clinic
Address:
City:
Kewanee
Zip:
61443
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
309-243-3605
Email:
andersonj@illinoiscancercare.com
Investigator:
Last name:
Bryan A. Faller
Email:
Principal Investigator
Facility:
Name:
Illinois CancerCare-Macomb
Address:
City:
Macomb
Zip:
61455
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
309-243-3605
Email:
andersonj@illinoiscancercare.com
Investigator:
Last name:
Bryan A. Faller
Email:
Principal Investigator
Facility:
Name:
Carle Physician Group-Mattoon/Charleston
Address:
City:
Mattoon
Zip:
61938
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
800-446-5532
Email:
Research@carle.com
Investigator:
Last name:
Suparna Mantha
Email:
Principal Investigator
Facility:
Name:
Cancer Care Center of O'Fallon
Address:
City:
O'Fallon
Zip:
62269
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
217-876-4762
Email:
morganthaler.jodi@mhsil.com
Investigator:
Last name:
Bryan A. Faller
Email:
Principal Investigator
Facility:
Name:
Illinois CancerCare-Ottawa Clinic
Address:
City:
Ottawa
Zip:
61350
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
309-243-3605
Email:
andersonj@illinoiscancercare.com
Investigator:
Last name:
Bryan A. Faller
Email:
Principal Investigator
Facility:
Name:
Illinois CancerCare-Pekin
Address:
City:
Pekin
Zip:
61554
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
309-243-3605
Email:
andersonj@illinoiscancercare.com
Investigator:
Last name:
Bryan A. Faller
Email:
Principal Investigator
Facility:
Name:
Illinois CancerCare-Peoria
Address:
City:
Peoria
Zip:
61615
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
309-243-3605
Email:
andersonj@illinoiscancercare.com
Investigator:
Last name:
Bryan A. Faller
Email:
Principal Investigator
Facility:
Name:
Illinois CancerCare-Peru
Address:
City:
Peru
Zip:
61354
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
309-243-3605
Email:
andersonj@illinoiscancercare.com
Investigator:
Last name:
Bryan A. Faller
Email:
Principal Investigator
Facility:
Name:
Illinois CancerCare-Princeton
Address:
City:
Princeton
Zip:
61356
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
309-243-3605
Email:
andersonj@illinoiscancercare.com
Investigator:
Last name:
Bryan A. Faller
Email:
Principal Investigator
Facility:
Name:
Memorial Hospital East
Address:
City:
Shiloh
Zip:
62269
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
314-747-9912
Email:
dschwab@wustl.edu
Investigator:
Last name:
Patrick Grierson
Email:
Principal Investigator
Facility:
Name:
Southern Illinois University School of Medicine
Address:
City:
Springfield
Zip:
62702
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
217-545-7929
Investigator:
Last name:
Bryan A. Faller
Email:
Principal Investigator
Facility:
Name:
Springfield Clinic
Address:
City:
Springfield
Zip:
62702
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
800-444-7541
Investigator:
Last name:
Bryan A. Faller
Email:
Principal Investigator
Facility:
Name:
Springfield Memorial Hospital
Address:
City:
Springfield
Zip:
62781
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
217-528-7541
Email:
pallante.beth@mhsil.com
Investigator:
Last name:
Bryan A. Faller
Email:
Principal Investigator
Facility:
Name:
Carle Cancer Center
Address:
City:
Urbana
Zip:
61801
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
800-446-5532
Email:
Research@carle.com
Investigator:
Last name:
Suparna Mantha
Email:
Principal Investigator
Facility:
Name:
Illinois CancerCare - Washington
Address:
City:
Washington
Zip:
61571
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
309-243-3605
Email:
andersonj@illinoiscancercare.com
Investigator:
Last name:
Bryan A. Faller
Email:
Principal Investigator
Facility:
Name:
Northwest Cancer Center - Main Campus
Address:
City:
Crown Point
Zip:
46307
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
219-310-2550
Investigator:
Last name:
Suparna Mantha
Email:
Principal Investigator
Facility:
Name:
Northwest Oncology LLC
Address:
City:
Dyer
Zip:
46311
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
219-924-8178
Investigator:
Last name:
Suparna Mantha
Email:
Principal Investigator
Facility:
Name:
Northwest Cancer Center - Hobart
Address:
City:
Hobart
Zip:
46342
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
219-947-1795
Investigator:
Last name:
Suparna Mantha
Email:
Principal Investigator
Facility:
Name:
Saint Mary Medical Center
Address:
City:
Hobart
Zip:
46342
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
219-836-6875
Email:
CancerResearch@COMHS.org
Investigator:
Last name:
Suparna Mantha
Email:
Principal Investigator
Facility:
Name:
Saint Catherine Hospital
Address:
City:
Indianapolis
Zip:
46312
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Email:
ecog.rss@jimmy.harvard.edu
Investigator:
Last name:
Suparna Mantha
Email:
Principal Investigator
Facility:
Name:
The Community Hospital
Address:
City:
Munster
Zip:
46321
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
219-836-3349
Investigator:
Last name:
Suparna Mantha
Email:
Principal Investigator
Facility:
Name:
Women's Diagnostic Center - Munster
Address:
City:
Munster
Zip:
46321
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
219-934-8869
Email:
mnicholson@comhs.org
Investigator:
Last name:
Suparna Mantha
Email:
Principal Investigator
Facility:
Name:
Northwest Cancer Center - Valparaiso
Address:
City:
Valparaiso
Zip:
46383
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
219-836-6875
Email:
CancerResearch@COMHS.org
Investigator:
Last name:
Suparna Mantha
Email:
Principal Investigator
Facility:
Name:
Mary Greeley Medical Center
Address:
City:
Ames
Zip:
50010
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
515-956-4132
Investigator:
Last name:
Joseph J. Merchant
Email:
Principal Investigator
Facility:
Name:
McFarland Clinic - Ames
Address:
City:
Ames
Zip:
50010
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
515-239-4734
Email:
ksoder@mcfarlandclinic.com
Investigator:
Last name:
Joseph J. Merchant
Email:
Principal Investigator
Facility:
Name:
Mission Cancer and Blood - Ankeny
Address:
City:
Ankeny
Zip:
50023
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
515-282-2921
Investigator:
Last name:
Richard L. Deming
Email:
Principal Investigator
Facility:
Name:
McFarland Clinic - Boone
Address:
City:
Boone
Zip:
50036
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
515-956-4132
Investigator:
Last name:
Joseph J. Merchant
Email:
Principal Investigator
Facility:
Name:
Iowa Methodist Medical Center
Address:
City:
Des Moines
Zip:
50309
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
515-241-6727
Investigator:
Last name:
Seema Harichand-Herdt
Email:
Principal Investigator
Facility:
Name:
Mission Cancer and Blood - Des Moines
Address:
City:
Des Moines
Zip:
50309
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
515-241-3305
Investigator:
Last name:
Seema Harichand-Herdt
Email:
Principal Investigator
Facility:
Name:
Mercy Medical Center - Des Moines
Address:
City:
Des Moines
Zip:
50314
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
515-358-6613
Email:
cancerresearch@mercydesmoines.org
Investigator:
Last name:
Richard L. Deming
Email:
Principal Investigator
Facility:
Name:
McFarland Clinic - Trinity Cancer Center
Address:
City:
Fort Dodge
Zip:
50501
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
515-956-4132
Investigator:
Last name:
Joseph J. Merchant
Email:
Principal Investigator
Facility:
Name:
McFarland Clinic - Jefferson
Address:
City:
Jefferson
Zip:
50129
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
515-956-4132
Investigator:
Last name:
Joseph J. Merchant
Email:
Principal Investigator
Facility:
Name:
McFarland Clinic - Marshalltown
Address:
City:
Marshalltown
Zip:
50158
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
515-956-4132
Investigator:
Last name:
Joseph J. Merchant
Email:
Principal Investigator
Facility:
Name:
UMass Memorial Medical Center - University Campus
Address:
City:
Worcester
Zip:
01655
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
508-856-3216
Email:
cancer.research@umassmed.edu
Investigator:
Last name:
Sowmya Korapati
Email:
Principal Investigator
Facility:
Name:
Trinity Health Saint Joseph Mercy Hospital Ann Arbor
Address:
City:
Ann Arbor
Zip:
48106
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
734-712-7251
Email:
MCRCwebsitecontactform@stjoeshealth.org
Investigator:
Last name:
Tareq Al baghdadi
Email:
Principal Investigator
Facility:
Name:
Bronson Battle Creek
Address:
City:
Battle Creek
Zip:
49017
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
616-391-1230
Email:
crcwm-regulatory@crcwm.org
Investigator:
Last name:
Kathleen J. Yost
Email:
Principal Investigator
Facility:
Name:
Trinity Health IHA Medical Group Hematology Oncology - Brighton
Address:
City:
Brighton
Zip:
48114
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
734-712-7251
Email:
MCRCwebsitecontactform@stjoeshealth.org
Investigator:
Last name:
Tareq Al baghdadi
Email:
Principal Investigator
Facility:
Name:
Trinity Health Medical Center - Brighton
Address:
City:
Brighton
Zip:
48114
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
734-712-7251
Email:
MCRCwebsitecontactform@stjoeshealth.org
Investigator:
Last name:
Tareq Al baghdadi
Email:
Principal Investigator
Facility:
Name:
Trinity Health IHA Medical Group Hematology Oncology - Canton
Address:
City:
Canton
Zip:
48188
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
734-712-7251
Email:
MCRCwebsitecontactform@stjoeshealth.org
Investigator:
Last name:
Tareq Al baghdadi
Email:
Principal Investigator
Facility:
Name:
Trinity Health Medical Center - Canton
Address:
City:
Canton
Zip:
48188
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
734-712-7251
Email:
MCRCwebsitecontactform@stjoeshealth.org
Investigator:
Last name:
Tareq Al baghdadi
Email:
Principal Investigator
Facility:
Name:
Chelsea Hospital
Address:
City:
Chelsea
Zip:
48118
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
734-712-7251
Email:
MCRCwebsitecontactform@stjoeshealth.org
Investigator:
Last name:
Tareq Al baghdadi
Email:
Principal Investigator
Facility:
Name:
Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital
Address:
City:
Chelsea
Zip:
48118
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
734-712-7251
Email:
MCRCwebsitecontactform@stjoeshealth.org
Investigator:
Last name:
Tareq Al baghdadi
Email:
Principal Investigator
Facility:
Name:
Henry Ford Health Saint John Hospital
Address:
City:
Detroit
Zip:
48236
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
313-343-3166
Email:
Kkeenan1@hfhs.org
Investigator:
Last name:
Tareq Al baghdadi
Email:
Principal Investigator
Facility:
Name:
Henry Ford River District Hospital
Address:
City:
East China Township
Zip:
48054
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
313-343-3166
Email:
kforman1@hfhs.org
Investigator:
Last name:
Tareq Al baghdadi
Email:
Principal Investigator
Facility:
Name:
Genesee Cancer and Blood Disease Treatment Center
Address:
City:
Flint
Zip:
48503
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
810-762-8038
Email:
wstrong@ghci.org
Investigator:
Last name:
Tareq Al baghdadi
Email:
Principal Investigator
Facility:
Name:
Genesee Hematology Oncology PC
Address:
City:
Flint
Zip:
48503
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
810-762-8038
Email:
wstrong@ghci.org
Investigator:
Last name:
Tareq Al baghdadi
Email:
Principal Investigator
Facility:
Name:
Genesys Hurley Cancer Institute
Address:
City:
Flint
Zip:
48503
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
810-762-8038
Email:
wstrong@ghci.org
Investigator:
Last name:
Tareq Al baghdadi
Email:
Principal Investigator
Facility:
Name:
Corewell Health Grand Rapids Hospitals - Butterworth Hospital
Address:
City:
Grand Rapids
Zip:
49503
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
616-391-1230
Email:
crcwm-regulatory@crcwm.org
Investigator:
Last name:
Kathleen J. Yost
Email:
Principal Investigator
Facility:
Name:
Great Lakes Cancer Management Specialists-Van Elslander Cancer Center
Address:
City:
Grosse Pointe Woods
Zip:
48236
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
313-343-3166
Email:
kforman1@hfhs.org
Investigator:
Last name:
Tareq Al baghdadi
Email:
Principal Investigator
Facility:
Name:
Henry Ford Saint John Hospital - Breast
Address:
City:
Grosse Pointe Woods
Zip:
48236
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
313-343-3166
Email:
karen.forman@ascension.org
Investigator:
Last name:
Tareq Al baghdadi
Email:
Principal Investigator
Facility:
Name:
Bronson Methodist Hospital
Address:
City:
Kalamazoo
Zip:
49007
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
616-391-1230
Email:
crcwm-regulatory@crcwm.org
Investigator:
Last name:
Kathleen J. Yost
Email:
Principal Investigator
Facility:
Name:
West Michigan Cancer Center
Address:
City:
Kalamazoo
Zip:
49007
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
616-391-1230
Email:
crcwm-regulatory@crcwm.org
Investigator:
Last name:
Kathleen J. Yost
Email:
Principal Investigator
Facility:
Name:
Ascension Borgess Cancer Center
Address:
City:
Kalamazoo
Zip:
49009
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
616-391-1230
Email:
crcwm-regulatory@crcwm.org
Investigator:
Last name:
Kathleen J. Yost
Email:
Principal Investigator
Facility:
Name:
Trinity Health Saint Mary Mercy Livonia Hospital
Address:
City:
Livonia
Zip:
48154
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
734-712-7251
Email:
MCRCwebsitecontactform@stjoeshealth.org
Investigator:
Last name:
Tareq Al baghdadi
Email:
Principal Investigator
Facility:
Name:
Henry Ford Saint John Hospital - Macomb Medical
Address:
City:
Macomb
Zip:
48044
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
313-343-3166
Email:
kforman1@hfhs.org
Investigator:
Last name:
Tareq Al baghdadi
Email:
Principal Investigator
Facility:
Name:
Henry Ford Warren Hospital - Breast Macomb
Address:
City:
Macomb
Zip:
48044
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
313-343-3166
Email:
kforman1@hfhs.org
Investigator:
Last name:
Tareq Al baghdadi
Email:
Principal Investigator
Facility:
Name:
Trinity Health Muskegon Hospital
Address:
City:
Muskegon
Zip:
49444
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
616-391-1230
Email:
crcwm-regulatory@crcwm.org
Investigator:
Last name:
Kathleen J. Yost
Email:
Principal Investigator
Facility:
Name:
Corewell Health Lakeland Hospitals - Niles Hospital
Address:
City:
Niles
Zip:
49120
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
616-391-1230
Investigator:
Last name:
Kathleen J. Yost
Email:
Principal Investigator
Facility:
Name:
Cancer and Hematology Centers of Western Michigan - Norton Shores
Address:
City:
Norton Shores
Zip:
49444
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
616-391-1230
Email:
connie.szczepanek@crcwm.org
Investigator:
Last name:
Kathleen J. Yost
Email:
Principal Investigator
Facility:
Name:
Corewell Health Reed City Hospital
Address:
City:
Reed City
Zip:
49677
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
616-391-1230
Email:
crcwm-regulatory@crcwm.org
Investigator:
Last name:
Kathleen J. Yost
Email:
Principal Investigator
Facility:
Name:
MyMichigan Medical Center Saginaw
Address:
City:
Saginaw
Zip:
48601
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
734-712-7251
Email:
MCRCwebsitecontactform@stjoeshealth.org
Investigator:
Last name:
Tareq Al baghdadi
Email:
Principal Investigator
Facility:
Name:
Oncology Hematology Associates of Saginaw Valley PC
Address:
City:
Saginaw
Zip:
48604
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
989-907-8411
Email:
lori.srebinski@ascension.org
Investigator:
Last name:
Tareq Al baghdadi
Email:
Principal Investigator
Facility:
Name:
Corewell Health Lakeland Hospitals - Marie Yeager Cancer Center
Address:
City:
Saint Joseph
Zip:
49085
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
616-391-1230
Email:
crcwm-regulatory@crcwm.org
Investigator:
Last name:
Kathleen J. Yost
Email:
Principal Investigator
Facility:
Name:
MyMichigan Medical Center Tawas
Address:
City:
Tawas City
Zip:
48764
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
734-712-7251
Email:
MCRCwebsitecontactform@stjoeshealth.org
Investigator:
Last name:
Tareq Al baghdadi
Email:
Principal Investigator
Facility:
Name:
Munson Medical Center
Address:
City:
Traverse City
Zip:
49684
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
616-391-1230
Email:
crcwm-regulatory@crcwm.org
Investigator:
Last name:
Kathleen J. Yost
Email:
Principal Investigator
Facility:
Name:
Henry Ford Health Warren Hospital
Address:
City:
Warren
Zip:
48093
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
313-343-3166
Email:
kforman1@hfhs.org
Investigator:
Last name:
Tareq Al baghdadi
Email:
Principal Investigator
Facility:
Name:
Henry Ford Madison Heights Hospital - Breast
Address:
City:
Warren
Zip:
48093
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
313-343-3166
Email:
kforman1@hfhs.org
Investigator:
Last name:
Tareq Al baghdadi
Email:
Principal Investigator
Facility:
Name:
Henry Ford Warren Hospital - GLCMS
Address:
City:
Warren
Zip:
48093
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
313-343-3166
Email:
kforman1@hfhs.org
Investigator:
Last name:
Tareq Al baghdadi
Email:
Principal Investigator
Facility:
Name:
Saint Mary's Oncology/Hematology Associates of West Branch
Address:
City:
West Branch
Zip:
48661
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
989-907-8411
Email:
lori.srebinski@ascension.org
Investigator:
Last name:
Tareq Al baghdadi
Email:
Principal Investigator
Facility:
Name:
University of Michigan Health - West
Address:
City:
Wyoming
Zip:
49519
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
616-391-1230
Email:
crcwm-regulatory@crcwm.org
Investigator:
Last name:
Kathleen J. Yost
Email:
Principal Investigator
Facility:
Name:
Huron Gastroenterology PC
Address:
City:
Ypsilanti
Zip:
48106
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
734-712-7251
Email:
MCRCwebsitecontactform@stjoeshealth.org
Investigator:
Last name:
Tareq Al baghdadi
Email:
Principal Investigator
Facility:
Name:
Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus
Address:
City:
Ypsilanti
Zip:
48197
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
734-712-7251
Email:
MCRCwebsitecontactform@stjoeshealth.org
Investigator:
Last name:
Tareq Al baghdadi
Email:
Principal Investigator
Facility:
Name:
Mercy Hospital
Address:
City:
Coon Rapids
Zip:
55433
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
952-993-1517
Email:
mmcorc@healthpartners.com
Investigator:
Last name:
David M. King
Email:
Principal Investigator
Facility:
Name:
Fairview Southdale Hospital
Address:
City:
Edina
Zip:
55435
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
952-993-1517
Email:
mmcorc@healthpartners.com
Investigator:
Last name:
David M. King
Email:
Principal Investigator
Facility:
Name:
Abbott-Northwestern Hospital
Address:
City:
Minneapolis
Zip:
55407
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
952-993-1517
Email:
mmcorc@healthpartners.com
Investigator:
Last name:
David M. King
Email:
Principal Investigator
Facility:
Name:
Mayo Clinic in Rochester
Address:
City:
Rochester
Zip:
55905
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
855-776-0015
Investigator:
Last name:
Mohamad B. Sonbol
Email:
Principal Investigator
Facility:
Name:
Regions Hospital
Address:
City:
Saint Paul
Zip:
55101
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
952-993-1517
Email:
mmcorc@healthpartners.com
Investigator:
Last name:
David M. King
Email:
Principal Investigator
Facility:
Name:
United Hospital
Address:
City:
Saint Paul
Zip:
55102
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
952-993-1517
Email:
mmcorc@healthpartners.com
Investigator:
Last name:
David M. King
Email:
Principal Investigator
Facility:
Name:
Saint Francis Medical Center
Address:
City:
Cape Girardeau
Zip:
63703
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
573-334-2230
Email:
sfmc@sfmc.net
Investigator:
Last name:
Bryan A. Faller
Email:
Principal Investigator
Facility:
Name:
Siteman Cancer Center at West County Hospital
Address:
City:
Creve Coeur
Zip:
63141
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
800-600-3606
Email:
info@siteman.wustl.edu
Investigator:
Last name:
Patrick Grierson
Email:
Principal Investigator
Facility:
Name:
Parkland Health Center - Farmington
Address:
City:
Farmington
Zip:
63640
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
314-996-5569
Investigator:
Last name:
Bryan A. Faller
Email:
Principal Investigator
Facility:
Name:
Washington University School of Medicine
Address:
City:
Saint Louis
Zip:
63110
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
800-600-3606
Email:
info@siteman.wustl.edu
Investigator:
Last name:
Patrick Grierson
Email:
Principal Investigator
Facility:
Name:
Siteman Cancer Center-South County
Address:
City:
Saint Louis
Zip:
63129
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
800-600-3606
Email:
info@siteman.wustl.edu
Investigator:
Last name:
Patrick Grierson
Email:
Principal Investigator
Facility:
Name:
Missouri Baptist Medical Center
Address:
City:
Saint Louis
Zip:
63131
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
314-996-5569
Investigator:
Last name:
Bryan A. Faller
Email:
Principal Investigator
Facility:
Name:
Siteman Cancer Center at Christian Hospital
Address:
City:
Saint Louis
Zip:
63136
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
800-600-3606
Email:
info@siteman.wustl.edu
Investigator:
Last name:
Patrick Grierson
Email:
Principal Investigator
Facility:
Name:
Siteman Cancer Center at Saint Peters Hospital
Address:
City:
Saint Peters
Zip:
63376
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
800-600-3606
Email:
info@siteman.wustl.edu
Investigator:
Last name:
Patrick Grierson
Email:
Principal Investigator
Facility:
Name:
Sainte Genevieve County Memorial Hospital
Address:
City:
Sainte Genevieve
Zip:
63670
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
314-996-5569
Investigator:
Last name:
Bryan A. Faller
Email:
Principal Investigator
Facility:
Name:
Missouri Baptist Sullivan Hospital
Address:
City:
Sullivan
Zip:
63080
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
314-996-5569
Investigator:
Last name:
Bryan A. Faller
Email:
Principal Investigator
Facility:
Name:
BJC Outpatient Center at Sunset Hills
Address:
City:
Sunset Hills
Zip:
63127
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
314-996-5569
Investigator:
Last name:
Bryan A. Faller
Email:
Principal Investigator
Facility:
Name:
Mount Sinai West
Address:
City:
New York
Zip:
10019
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
212-824-7309
Email:
CCTO@mssm.edu
Investigator:
Last name:
Lakshmi Rajdev
Email:
Principal Investigator
Facility:
Name:
Mount Sinai Hospital
Address:
City:
New York
Zip:
10029
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
212-824-7309
Email:
CCTO@mssm.edu
Investigator:
Last name:
Lakshmi Rajdev
Email:
Principal Investigator
Facility:
Name:
University of Oklahoma Health Sciences Center
Address:
City:
Oklahoma City
Zip:
73104
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
405-271-8777
Email:
ou-clinical-trials@ouhsc.edu
Investigator:
Last name:
Sagila George
Email:
Principal Investigator
Facility:
Name:
Providence Newberg Medical Center
Address:
City:
Newberg
Zip:
97132
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
503-215-2614
Email:
CanRsrchStudies@providence.org
Investigator:
Last name:
Alison K. Conlin
Email:
Principal Investigator
Facility:
Name:
Providence Willamette Falls Medical Center
Address:
City:
Oregon City
Zip:
97045
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
503-215-2614
Email:
CanRsrchStudies@providence.org
Investigator:
Last name:
Alison K. Conlin
Email:
Principal Investigator
Facility:
Name:
Providence Portland Medical Center
Address:
City:
Portland
Zip:
97213
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
503-215-2614
Email:
CanRsrchStudies@providence.org
Investigator:
Last name:
Alison K. Conlin
Email:
Principal Investigator
Facility:
Name:
Providence Saint Vincent Medical Center
Address:
City:
Portland
Zip:
97225
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
503-215-2614
Email:
CanRsrchStudies@providence.org
Investigator:
Last name:
Alison K. Conlin
Email:
Principal Investigator
Facility:
Name:
ECOG-ACRIN Cancer Research Group
Address:
City:
Philadelphia
Zip:
19103
Country:
United States
Status:
Recruiting
Contact:
Last name:
Lakshmi Rajdev
Email:
lakshmi.rajdev@mountsinai.org
Investigator:
Last name:
Lakshmi Rajdev
Email:
Principal Investigator
Facility:
Name:
VCU Massey Cancer Center at Stony Point
Address:
City:
Richmond
Zip:
23235
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Email:
ctoclinops@vcu.edu
Investigator:
Last name:
Jennifer L. Myers
Email:
Principal Investigator
Facility:
Name:
Virginia Commonwealth University/Massey Cancer Center
Address:
City:
Richmond
Zip:
23298
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Email:
CTOclinops@vcu.edu
Investigator:
Last name:
Jennifer L. Myers
Email:
Principal Investigator
Facility:
Name:
VCU Community Memorial Health Center
Address:
City:
South Hill
Zip:
23970
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Email:
nemer.elmouallem@vcuhealth.org
Investigator:
Last name:
Jennifer L. Myers
Email:
Principal Investigator
Facility:
Name:
University of Wisconsin Carbone Cancer Center - Eastpark Medical Center
Address:
City:
Madison
Zip:
53718
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
800-622-8922
Email:
clinicaltrials@cancer.wisc.edu
Investigator:
Last name:
Nataliya V. Uboha
Email:
Principal Investigator
Facility:
Name:
University of Wisconsin Carbone Cancer Center - University Hospital
Address:
City:
Madison
Zip:
53792
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
800-622-8922
Email:
clinicaltrials@cancer.wisc.edu
Investigator:
Last name:
Nataliya V. Uboha
Email:
Principal Investigator
Start date:
December 6, 2023
Completion date:
October 31, 2027
Lead sponsor:
Agency:
National Cancer Institute (NCI)
Agency class:
NIH
Source:
National Cancer Institute (NCI)
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT05836584
